Endpoints and assessment
PD‐L1, tumor, death, toxicities, Cancer
DISEASE PROGRESSION, TUMOR, CANCER
The primary endpoint was pathologic complete response (pCR), which was defined as no viable tumor cells identified in resected tissue (pT0N0). Secondary endpoints included pathologic downstaging (defined as pathologic stage < pT2N0), event‐free survival (EFS, defined as the time from initiation of chemo‐immunotherapy to disease progression, relapse after RC or death from any cause), OS (defined as the time from initiation of chemo‐immunotherapy to death from any cause), and safety. In addition, the study conducted PD‐L1 expression status and whole exoneme sequencing (WES) to explore the potential biomarkers for efficacy. The AEs were reported and graded by National Cancer Institute Common Terminology Criteria for AEs (version 5.0), and toxicities were assessed for 90 days after dosing was complete.